Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems

Alcohol

Volumn 43, Issue 1, 2009, Pages 65-71

  Cheng, Debbie M ^a,c   Libman, Howard ^b   Bridden, Carly ^a   Saitz, Richard ^a,c   Samet, Jeffrey H ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alcohol consumption; HIV; Lipodystrophy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SELF REPORT;

ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COCAINE-RELATED DISORDERS; COHORT STUDIES; DEPRESSIVE DISORDER; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58949085661     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.alcohol.2008.09.004     Document Type: Article

References (33)

1. Armellini F., Zamboni M., Frigo L., Mandragona R., Robbi R., Micciolo R., et al. Alcohol consumption, smoking habits and body fat distribution in Italian men and women aged 20-60 years. Eur. J. Clin. Nutr. 47 (1993) 52-60
2. Ben-Romano R., Rudich A., Torok D., Vanounou S., Riesenberg K., Schlaeffer F., et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 17 (2003) 23-32
3. Blanch J., Rousaud A., Martinez E., De Lazzari E., Milinkovic A., Peri J.M., et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin. Infect. Dis. 38 (2004) 1464-1470
4. Brinkman K., Smeitink J.A., Romijn J.A., and Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354 (1999) 1112-1115
5. Buchsbaum D.G., Buchanan R.G., Centor R.M., Schnoll S.H., and Lawton M.J. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann. Intern. Med. 115 (1991) 774-777
6. Carey K.B., Carey M.P., Maisto S.A., and Henson J.M. Temporal stability of the timeline followback interview for alcohol and drug use with psychiatric outpatients. J. Stud. Alcohol 65 (2004) 774-781
7. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., and Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50 (2001) 1378-1388
8. Carr A., Emery S., Law M., Puls R., Lundgren J.D., and Powderly W.G. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361 (2003) 726-735
9. Coin A., Sergi G., Enzi G., Busetto L., Pigozzo S., Lupoli L., et al. Total and regional body composition and energy expenditure in multiple symmetric lipomatosis. Clin. Nutr. 24 (2005) 367-374
10. Cook J.A., Cohen M.H., Burke J., Grey D., Anastos K., Kirstein L., et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J. Acquir. Immune Defic. Syndr. 30 (2002) 401-409
11. Enzi G., Busetto L., Ceschin E., Coin A., Digito M., and Pigozzo S. Multiple symmetric lipomatosis: clinical aspects and outcome in a long-term longitudinal study. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 253-261
12. Enzi G., Inelmen E.M., Baritussio A., Dorigo P., Prosdocimi M., and Mazzoleni F. Multiple symmetric lipomatosis: a defect in adrenergic-stimulated lipolysis. J. Clin. Invest. 60 (1977) 1221-1229
13. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
14. Galli M., Cozzi-Lepri A., Ridolfo A.L., Gervasoni C., Ravasio L., Corsico L., et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch. Intern. Med. 162 (2002) 2621-2628
15. Heath K.V., Hogg R.S., Singer J., Chan K.J., O'Shaughnessy M.V., and Montaner J.S. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J. Acquir. Immune Defic. Syndr. 30 (2002) 440-447
16. Hengel R.L., Watts N.B., and Lennox J.L. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350 (1997) 1596
17. Klopstock T., Naumann M., Seibel P., Shalke B., Reiners K., and Reichmann H. Mitochondrial DNA mutations in multiple symmetric lipomatosis. Mol. Cell. Biochem. 174 (1997) 271-275
18. Koppes L.L., Kemper H.C., Post G.B., Snel J., and Twisk J.W. Development and stability of alcohol consumption from adolescence into adulthood: the Amsterdam Growth and Health Longitudinal Study. Eur. Addict. Res. 6 (2000) 183-188
19. Martinez E., Garcia-Viejo M.A., Blanch L., and Gatell J.M. Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 24 (2001) 157-166
20. Martinez E., Mocroft A., Garcia-Viejo M.A., Perez-Cuevas J.B., Blanco J.L., Mallolas J., et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357 (2001) 592-598
21. Mayfield D., McLeod G., and Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am. J. Psychiatry 131 (1974) 1121-1123
22. McComsey G.A., and Walker U.A. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion 4 (2004) 111-118
23. Mujawar Z., Rose H., Morrow M.P., Pushkarsky T., Dubrovsky L., Mukhamedova N., et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 4 (2006) e365
24. National Institute on Alcohol Abuse and Alcoholism. (2005). Helping Patients Who Drink Too Much: A Clinician's Guide. Washington, DC: National Institute on Alcohol Abuse and Alcoholism; Updated 2005 edition. Available at: http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/ guide.pdf. Accessed October 24, 2007.
25. Robins L.N., Wing J., Wittchen H.U., Helzer J.E., Babor T.F., Burke J., et al. The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch. Gen. Psychiatry 45 (1988) 1069-1077
26. Samet J.H., Horton N.J., Meli S., Freedberg K.A., and Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol. Clin. Exp. Res. 28 (2004) 572-577
27. Samet J.H., Libman H., LaBelle C., Steger K., Lewis R., Craven D.E., et al. A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus. Arch. Intern. Med. 155 (1995) 1629-1633
28. Sattler F. Body habitus changes related to lipodystrophy. Clin. Infect. Dis. 36 (2003) S84-S90
29. Schoffer K., and Grant I. Multiple lipomas, alcoholism, and neuropathy: Madelung's disease or MERRF?. Muscle Nerve 33 (2006) 142-146
30. Smith K.L., Horton N.J., Saitz R., and Samet J.H. The use of the mini-mental state examination in recruitment for substance abuse research studies. Drug Alcohol Depend. 82 (2006) 231-237
31. Sobell L.C., and Sobell M.B. Alcohol Timeline Followback (TFLB). In: American Psychiatric Association (Ed). Handbook of Psychiatric Measures (1996), American Psychiatric Association, Washington, DC 477-479
32. Teplitsky V., and Halabe A. Fat distribution in AIDS. N. Engl. J. Med. 340 (1999) 969-970
33. Villarroya F., Domingo P., and Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int. J. Obes. (Lond.) 31 (2007) 1763-1776